<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>爵士製藥（Jazz Pharmaceuticals plc，股票代碼：JAZZ）宣佈了第三階段 HERIZON-GEA-01 試驗的積極療效和安全性結果，該試驗評估了 Ziihera 與化療聯合使用（無論是否與 PD-1 抑制劑 Tevimbra 聯合使用）作為 HER2 陽性局部晚期或轉移性胃食管腺癌成年患者的一線治療，包括胃癌、胃食管交界癌和食管癌。</p>
<p>研究發現，兩個實驗組，即 Ziihera 加 tislelizumab 和化療，以及 Ziihera 加化療，均導致無進展生存期的統計學顯著延長，疾病進展或死亡風險減少約 35%，與 trastuzumab 加化療相比具有臨牀意義。</p>
<p>欲獲取更多健康新聞，請訪問 rttnews.com。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

爵士制藥

<p>爵士製藥（Jazz Pharmaceuticals plc，股票代碼：JAZZ）報告了 HERIZON-GEA-01 三期臨牀試驗的積極結果，該試驗評估了 Ziihera 與化療聯合使用（可選配 PD-1 抑制劑 Tevimbra）在治療 HER2 陽性局部晚期或轉移性胃食管腺癌成人患者中的效果。研究顯示，進展無生存期顯著延長，與曲妥珠單抗加化療相比，疾病進展或死亡風險降低了 35%</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Jazz Pharmaceuticals plc (JAZZ) announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as first-line treatment for adults with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma, including cancers of the stomach, gastroesophageal junction and esophagus.</p>
<div class="lb-trans"><p>爵士製藥（Jazz Pharmaceuticals plc，股票代碼：JAZZ）宣佈了第三階段 HERIZON-GEA-01 試驗的積極療效和安全性結果，該試驗評估了 Ziihera 與化療聯合使用（無論是否與 PD-1 抑制劑 Tevimbra 聯合使用）作為 HER2 陽性局部晚期或轉移性胃食管腺癌成年患者的一線治療，包括胃癌、胃食管交界癌和食管癌。</p>
</div><p>The study found both investigational arms, Ziihera plus tislelizumab and chemotherapy, and Ziihera plus chemotherapy, led to a statistically significant and clinically meaningful prolongation of progression-free survival with approximately 35% reduction in the risk of disease progression or death versus trastuzumab plus chemotherapy.</p>
<div class="lb-trans"><p>研究發現，兩個實驗組，即 Ziihera 加 tislelizumab 和化療，以及 Ziihera 加化療，均導致無進展生存期的統計學顯著延長，疾病進展或死亡風險減少約 35%，與 trastuzumab 加化療相比具有臨牀意義。</p>
</div><p>For More Such Health News, visit rttnews.com.</p>
<div class="lb-trans"><p>欲獲取更多健康新聞，請訪問 rttnews.com。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

爵士製藥公佈了第三階段 HERIZON-GEA-01 試驗的積極結果